be less frequent, there remains significant concern regarding management of bleeding events when they occur. 12 The anticoagulant effect of VKAs can be reversed with vitamin K, as well as coagulation factor replacement using prothrombin complex concentrates (PCCs) or plasma. 13 The degree of VKA anticoagulation and its reversal can be monitored with the international normalized ratio (INR). While dabigatran can be reversed using idarucizumab, there are no specific reversal agents for factor Xa inhibitors. The objective of this narrative review is to provide a comprehensive summary of the evidence regarding pharmacological reversal of DOAC anticoagulant effect.
| PREPARING FOR REVERSAL: ARE CLINICALLY SIGNIFICANT DOAC LEVELS PRESENT?

| General considerations
Anticoagulant reversal agents and hemostatic products are generally reserved for emergency situations when rapid establishment of normal hemostasis is desired such as severe, refractory and life-threatening bleeding, and urgent surgery. When considering whether DOAC reversal is required, determining the likely presence of clinically significant drug levels should begin by documenting the type of DOAC taken (including frequency and dosing) and the timing of the last dose. Although DOACs have short half-lives typically ranging between 5 and 17 hours, [14] [15] [16] metabolic derangements (such as renal or liver failure) can influence DOAC plasma concentration and the expected duration of clinically significant drug levels in a given patient. A medication review should identify drug interactions which may influence DOAC levels (eg, inducers or inhibitors of Pg-P or CYP3A4) and/or contribute to bleeding (eg, antiplatelet therapy).
| Coagulation testing
Although DOACs do not require routine laboratory monitoring of anticoagulant effect, laboratory assessment of hemostasis is useful for emergency situations where DOAC reversal is being contemplated. Unlike VKA anticoagulants for which the INR is used to determine the degree of anticoagulation, routine coagulation testing such as the INR, prothrombin time (PT), and activated partial thromboplastin time (aPTT) do not reliably reflect the presence or degree of DOAC anticoagulant effect. 17, 18 Specialized assays which reliably measure DOAC levels are not widely available, particularly for emergency assessment.
Because of their limited sensitivity and reliability, 17, 18 routine coagulation tests (PT/INR, aPTT) must be interpreted in light of the clinical context, timing of last dose, and renal function (particularly for dabigatran). These tests can provide qualitative information regarding the presence or absence of clinically significant drug levels (ie, typical on-therapy or above-therapy levels). For example, the thrombin time (TT) is very sensitive to the presence of any dabigatran and a normal TT likely excludes clinically significant levels of dabigatran. [19] [20] [21] The sensitivity of aPTT for detecting dabigatran is variable, but a prolonged aPTT suggests clinically significant dabigatran levels (especially if using a sensitive assay). 22 The most accurate and reliable tests for measuring dabigatran levels are the dilute thrombin time (dTT), ecarin clotting time (ECT), and ecarin chromogenic assay (ECA). 18, 19, 21 The PT can be helpful for determining the presence of rivaroxaban and edoxaban, where a prolonged PT suggests clinically significant drug levels. 23, 24 However, a normal PT may not exclude clinically significant levels of rivaroxaban or edoxaban. 24 The PT and aPTT are relatively insensitive to apixaban and should not be used to exclude the presence of apixaban. 17, 18 A prolonged PT suggests clinically significant apixaban levels. 17 The most accurate and reliable tests for measuring factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) is a chromogenic anti-Xa activity assay calibrated to the drug of interest. 25 If a drugspecific calibrated anti-Xa assay is unavailable, calibration with a low molecular weight heparin standard can be used to exclude clinically significant drug levels (but not quantitation). 18 Further, assessment of DOAC plasma levels is complicated by a lack of established therapeutic ranges. 17, 18 Typical "on therapy"
drug levels represent those measured in pharmacokinetic studies and clinical trials. Threshold DOAC levels below which hemostasis is considered "normal" for both bleeding complications and surgical intervention are uncertain. 
| Thrombin generation assays and thromboelastography
Global coagulation tests such as thrombin generation assays (TGAs), thromboelastrography (TEG) or ROTEM are under study for determining DOAC anticoagulant effect and the efficacy of reversal strategies. [27] [28] [29] TGAs quantify the rate and amount of thrombin generation as a surrogate marker for fibrin clot formation. TEG/ROTEM measure the forces created by the formation of a clot, which provides information on the rate of clot formation, as well as clot strength and fibrinolysis. Both TGAs and TEG/ROTEM report kinetic/latency parameters (time to significant clot/thrombin endpoint) and quantitative parameters (amount of thrombin generation/strength of clot). With respect to TGAs, the kinetic parameters include the lag time (LT) and time-to-peak thrombin generation (TTP), whereas the quantitative parameters usually reported are the endogenous thrombin potential (ETP) and peak thrombin generation. 30 Rivaroxaban has been shown to inhibit both kinetic and quantitative TGA parameters. 31 Argatroban, a direct thrombin inhibitor similar to dabigatran, has been shown to also affect kinetic and quantitative TGA parameters. 32 
| Idarucizumab for dabigatran reversal
Idarucizumab is a humanized, monoclonal antibody fragment against dabigatran 34 that binds to dabigatran with high affinity (approximately 350-fold that of thrombin), thereby effectively preventing dabigatran from interacting with its therapeutic target. 34 In phase I/II studies, idarucizumab rapidly and fully reversed dabigatran anticoagulation, as assessed by clotting assays such as the dTT and ECT, and reduction in unbound (active) dabigatran. 35 Reversal of dabigatran-anticoagulant effect by idarucizumab has been demonstrated in both young healthy adults, 35 as well as older volunteer subjects with mild to moderate renal dysfunction based on correction of laboratory parameters and reduction of unbound dabigatran. 36 The prospective cohort REVERSE-AD study evaluated idarucizumab (5 g intravenously) in dabigatran-treated patients with major bleeding (n = 301) or requiring emergent procedures or surgery (n = 202). 37 Median correction of anticoagulant effect was 100% (95% CI 100-100) based on correction of prolonged dTT and ECT. Although hemostatic efficacy was included as an outcome, the clinical assessment of hemostasis can be subjective, and cessation of bleeding is often difficult to ascertain, depending on the site of Thrombotic complications have been reported with use of PCC, aPCC, and rFVIIa. [43] [44] [45] [46] It remains unclear whether PCC possesses a direct prothrombotic effect at doses used for VKA reversal, or whether thrombotic complications that occur following its use are due to the patients' underlying thrombotic risk and withdrawal of anticoagulation in the setting of an acute bleeding event. There was no difference in the incidence of thrombotic events in randomized controlled trials of VKA reversal with PCC compared to plasma for major bleeding 47 or urgent surgery. 48 In a meta-analysis of PCC for VKA reversal, the incidence of thromboembolic complications was 1.4%, although the reported thrombotic complication rates in individual studies vary widely. 49 Activated PCCs were associated with an incidence of thrombotic events of approximately 4:100 000 FEIBA infusions when used in hemophiliacs. 45 The thrombotic risk associated with the use of FEIBA in patients for VKA/DOAC reversal or PCC for DOAC reversal remains unclear, although a few small prospective cohort studies, as well as a small retrospective review revealed relatively low 30-day thrombotic complication rates.
50-52
A growing body of evidence reviewed herein suggests that PCCs and aPCC may be useful adjunctive therapies to promote hemostasis for DOAC-associated life-threatening bleeding. However, there is a lack of high-quality evidence for hemostatic efficacy and safety of PCC, aPCC, and rVIIa in patients requiring urgent DOAC reversal for bleeding or urgent surgery. Thus far, the majority of this evidence is limited to studies in which PCC, aPCC, or rVIIa were added in vitro to plasma from healthy volunteers receiving DOACs, as well as animal models evaluating hemostatic efficacy using various bleeding models. In vivo use of these prohemostatic agents in bleeding patients has been limited to case reports/series, as well as two small prospective cohort studies. 50, 51 When assessing the potential benefits and harms of these treatments, it is important to recognize that results from in vitro studies may not necessarily reflect hemostasis in vivo, and therefore, these studies should be interpreted with caution. Further, coagulation assays have variable sensitivity and reproducibility in the presence of DOACs as discussed above. The evidence presented herein should also be interpreted with the caveat that different assays, reagents, PCCs, PCC dosing and animal bleeding models were used in the various studies. This may partially account for some of the variation seen between the study outcomes. For the remainder of the review, we will refer to PCC, aPCC, and rFVIIa as "nonspecific prohemostatic agents".
| PCC, APCC, AND RECOMBINANT FACTOR VIIA FOR REVERSAL OF DABIGATRAN
A total of 14 studies evaluated dabigatran reversal with PCC, aPCC, or FVIIa, including eight animal model studies, [53] [54] [55] [56] [57] [58] [59] [60] five in vitro studies, [61] [62] [63] [64] [65] and one in vivo human volunteer study 66 (Tables S1-S3 ).
| Studies in animal models
| PCC
PCC reversed dabigatran's effect on ETP and increased peak thrombin generation. [57] [58] [59] [60] ETP overshoot was seen in all studies. Two studies showed complete reversal of dabigatran's effect on ROTEM/ TEG clotting time, 55, 60 while another two studies demonstrated a partial correction. 56, 59 With respect to hemostasis, five of six studies demonstrated at least partial hemostatic efficacy as measured by hematoma expansion, blood loss, bleeding time, or time to hemostasis, 53, 55, 57, 58, 60 whereas one study did not show a significant difference in blood loss following PCC administration. 
| aPCC
The majority of studies (four of six) showed no effect of aPCC on coagulation assays, with the exception of two separate studies in which the aPTT 60 and ECT 57 were partially corrected. When combined with rVIIa, partial correction of the aPTT and TT was achieved. 54 aPCC reversed dabigatran's effect on ETP 57 and partially corrected ROTEM clotting time. 56 The effect of aPCC on hemostasis was less certain with one study showing reduced bleeding time 57 and another study which failed to show an effect on bleeding time and volume of blood loss. 55 
| rVIIa
Overall, rVIIa had no effect on the aPTT, TT, dTT, and ECT with the exception of one study showing partial correction of aPTT. A total of four studies evaluated the impact of rFVIIa on hemostasis, with three studies demonstrating a significant benefit.
54,57,58
| Studies in human volunteer subjects
All studies that incorporated TGAs for dabigatran reversal demonstrated significant improvements in ETP and peak thrombin generation following PCC administration [61] [62] [63] [64] (Table S3) . ETP overshoot was seen in two studies. 61, 63 PCC administration had a variable effect on the kinetic parameters of the TGAs, demonstrating a significant improvement in lag time in three out of five studies assessing this parameter. [62] [63] [64] PCC had no effect on TTP in two studies. 61, 63 All human studies evaluating aPCC demonstrated at least a partial significant correction in both kinetic and quantitative TGA parameters. [62] [63] [64] Human studies evaluating rFVIIa demonstrated a significant impact on TGA kinetic parameters, but failed to show any benefit with respect to TGA quantitative parameters. [61] [62] [63] The single in vivo human study reported that no thrombotic events were observed during the 24 hours following 4FPCC administration, although this study only had 12 patients in total, and is underpowered to detect thrombotic events. 66 
| Dabigatran-treated patients with bleeding
A small prospective cohort study evaluated the use of aPCC (FEIBA) in 14 patients with dabigatran-associated bleeding. 
| Thrombotic indices
TA B L E 2 Xa inhibitor animal studies-PCC/aPCC/rFVIIa hemostasis/thrombosis results
Animal studies
Xa inhibitor
Bleeding model
Products evaluated
Hemostatic efficacy
Thrombotic complications
Godier et al. 4FPCC or TXA to healthy volunteers on rivaroxaban had no effect on bleeding duration or bleeding volume following skin punch biopsy. 
| aPCC
When added in vitro, aPCC partially corrected PT prolongation 30, 62, 63, 76, 79, 83 and abnormal anti-Xa activity. 83 aPCC restored thrombin generation indices in the majority of studies 30, [61] [62] [63] 76, 78, [80] [81] [82] with only one study showing an effect on ETP but no effect on lag time and time to peak. 80 ROTEM clotting time was corrected 63, 76, [78] [79] [80] [81] [82] in all but one study. 39 To our knowledge, aPCC has not been studied in vivo in humans.
| rVIIa
The majority of in vitro studies showed at least partial correction of prolonged PT. 30, 62, 63, 76, 77, 83 One in vitro study, showed partial TA B L E 3 Xa inhibitor human studies-PCC/aPCC/rFVIIa assay results ( ), no significant effect on coagulation parameter; ( ), significant correction in coagulation parameter; ( ), complete correction in coagulation parameter; ( ), ETP overshoot; ( ), not assessed. PCC, prothrombin complex concentrate; rFVIIa, recombinant factor VIIa; aPCC, activated prothrombin complex concentrate; TXA, tranexamic acid; aPTT, activated partial thromboplastin time; TT, thrombin time; dTT, dilute thrombin time; ECT, ecarin clotting time; LT, lag time; TTP, time to peak; ETP, endogenous thrombin potential; ROTEM, rotational thromboelastometry; TEG, thromboelastography.
reduction of anti-Xa activity with rFVIIa. 83 had experienced an intracranial hemorrhage as the initial bleeding event. Out of these 15 deaths, 14 were attributed to major bleeding, whereas a single fatal event was attributed to stroke 5 days post-4FPCC.
| Thrombotic indices
Three animal model studies evaluated the impact of prohemostatic agents on thrombogenesis, none of which demonstrated a significant thrombotic signal. 67, 71, 73 Prothrombotic laboratory markers were evaluated in one in vitro 83 and seven in vivo human volunteer studies studies. 66, 84, 85, [87] [88] [89] [90] Transient elevations in prothrombin fragment 1 + 2 were seen following 4FPCC infusion in two studies, 89, 90 with no significant impact on D-dimer values and no clinical thrombotic events in either study.
| P CC , AP CC , AND RECOMB INANT FAC TOR VIIA-SUMMARY
Overall, nonspecific prohemostatic agents such as PCC, aPCC, and rFVIIa may have some effect on reversal of DOAC anticoagulant effect as shown by an effect on laboratory parameters. However, these effects are overall modest and inconsistent between studies. This may be due to differences in study design, assays, reagents, as well as prohemostatic agents and dosing. This variation could also be because assays have not yet been optimized to adequately assess the effects of DOAC reversal using these nonspecific agents.
Idarucizumab is the agent of choice for dabigatran reversal for severe bleeding or urgent surgery in dabigatran-treated patients.
However, there are currently no approved specific reversal agents for the management of direct Xa inhibitor-associated bleeding.
Based on the evidence reviewed, PCC, aPCC, and rVIIa may have a role in promoting hemostasis in patients receiving factor Xa inhibitors, or in patients receiving dabigatran when idarucizumab is not readily available. Only PCC has been studied in vivo for factor Xa inhibitor reversal in humans. This, in addition to its wider availability and reduced cost compared to aPCC make it a reasonable first-line option for emergency reversal of factor Xa inhibitors. However, there remains significant uncertainty regarding efficacy and potential harms associated with these agents which should be used cautiously and in conjunction with maximal supportive measures, mechanical compression and definitive procedural/surgical intervention as required. Patients should be monitored for thrombotic complications following the administration of these agents, and consideration should be given to resuming anticoagulation once clinically appropriate.
The effect of nonspecific prohemostatic agents is particularly uncertain for DOAC-treated patients requiring urgent surgery.
Elective surgeries should be delayed, if possible, until adequate drug clearance can be achieved or assessment of DOAC levels can be assessed using reliable tests. This issue is further complicated by uncertainty regarding the DOAC levels that would provide adequate hemostasis to undertake surgery safely. Hemostasis may still be impaired following administration of one of these nonspecific agents, and high-bleed risk procedures (eg, spinal anesthesia)
should be avoided.
There is a lack of evidence regarding the dosing strategy for nonspecific hemostatic strategies. Initial dosing of PCC and aPCC at 50 IU/kg (maximum dose as per product monograph) has been suggested because some studies show incomplete correction of laboratory tests with lower doses. 53, 54, 67, 69, 89 The use of aPCC (FEIBA) at doses of 75-100 IU/kg has been studied exclusively in animal models or in vitro human studies, making dosing recommendations challenging and uncertain. 79, 81, 83 Dosing of rFVIIa in the animal studies highlighted above is highly variable, and in vitro addition to plasma was done using concentrations equivalent to 90-270 μg/kg.
| INVESTIGATIONAL DOAC REVERSAL AGENTS
| Andexanet Alfa for factor Xa inhibitor reversal
Andexanet alfa is a recombinant modified human factor Xa protein, currently undergoing clinical development. Andexanet alfa can bind to both direct (rivaroxaban, apixaban, edoxaban, betrixaban) and indirect (low molecular weight heparin, unfractionated heparin)
factor Xa inhibitors. 91 Because it lacks catalytic activity and a membrane binding domain, it acts as a decoy protein to sequester circulating factor Xa inhibitors, thereby preventing them from inhibiting endogenous factor Xa. Andexanet alfa has been shown to rapidly reverse the anticoagulant effects of rivaroxaban (ANNEXA-R) and apixaban (ANNEXA-A) in older healthy non-bleeding volunteers based on correction of anti-Xa activity. 92 The half-life of andexanet alfa is approximately 1 hour, 92 and as a result, it is given as a bolus followed by an infusion to produce sustained anticoagulation reversal.
ANNEXA-4 is an ongoing multicenter, open-label, prospective study evaluating andexanet alfa for reversal of Xa inhibitor anticoagulant effect in patients with major bleeding. 93 Apixabantreated patients, or rivaroxaban-treated patients who presented more than 7 hours after their last dose receive andexanet as a 400 mg intravenous (IV) bolus followed by a 480 mg 2-hour infusion. Rivaroxaban-treated patients with recent ingestion of rivaroxaban within 7 hours of presentation receive andexanet as an 800 mg bolus followed by a 960 mg 2-hour infusion. Higher doses of andexanet alfa are required for rivaroxaban due to higher initial plasma concentrations, as well as a larger volume of distribution. 92, [94] [95] [96] [97] In an interim analysis of ANNEXA-4, 67 patients received andexanet alfa for factor Xa inhibitor reversal (32 receiving rivaroxaban, 31 receiving apixaban, and 4 receiving enoxaparin). The relative reduction in anti-Xa activity at the end of the andexanet alfa bolus was 89% (95% CI 58-94) for rivaroxaban and 93% (95% CI 87-94) for apixaban and this reduction was sustained for the duration of the 2-hour infusion for both drugs. A rebound increase in anti-Xa activity was observed at the 4-hour measurement for both rivaroxaban and apixaban, after the 2-hour infusion was completed. Clinical hemostasis was assessed in this study, based on predefined criteria. Transient elevations in D-dimer and prothrombin fragment 1 + 2 levels were also noted following andexanet alfa administration in healthy individuals. 92 This is thought to be mediated by binding of andexanet alfa to tissue factor pathway inhibitor (TFPI). 98 Further study into a potential prothrombotic effect of andexanet alfa is warranted.
| Ciraparantag
Ciraparantag (PER977, aripazine) is a synthetic, rationally designed, small cationic molecule. 99 It was designed via in silico modelling to specifically bind directly to unfractionated heparin, low molecular weight heparin, dabigatran, rivaroxaban, apixaban, and edoxaban through noncovalent hydrogen bonding and charge-charge interactions without binding to human coagulation proteins or albumin. 99 Ciraparantag reversed rivaroxaban and apixaban-induced increases in anti-Xa activity in an in vitro human plasma study and reduced bleeding by >90% after tail transection in rats receiving dabigatran, rivaroxaban, and apixaban. 100 In this study, authors report that no procoagulant effects were observed following administration of ciraparantag in both rats and human plasma, although it is unclear how this was assessed. 100 Ciraparantag reduced blood loss in a rat-tail transection model evaluating dabigatran, rivaroxaban, apixaban, and edoxaban, while also restoring PT, aPTT, and TEG parameters to baseline. 101 There were no procoagulant effects observed in either rats or humans to date. 101 In a rabbit liver laceration model, both andexanet alfa and ciraparantag induced comparable and statistically significant reductions in blood loss at the highest doses studied. 102 
| CONCLUSIONS
DOAC reversal is indicated when rapid normalization of hemostasis is required for severe bleeding or urgent surgeries/procedures.
Idarucizumab is the recommended agent for dabigatran reversal for major bleeding or urgent surgery. PCC, aPCC, or rFVIIa may have a role in the setting of Xa-inhibitor associated bleeding, or when idarucizumab is not readily available for dabigatran-associated bleeding, but the efficacy of these agents and their optimal dosing is uncertain. Based on limited data, administration of PCC or aPCC at doses of 25-50 IU/kg is reasonable for DOAC-associated life-threatening bleeding. Andexanet alfa is currently under clinical development as a factor Xa inhibitor reversal agent, whereas ciraparantag is under development as a universal reversal agent.
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